Open access
Oct 2026
A Lymphoid-Enriched Spatial Immune Niche Defines an Immunotherapy-Responsive State in Hepatocellular Carcinoma
Background: Atezolizumab plus bevacizumab is a first-line therapy for advanced hepatocellular carcinoma (HCC), yet only a subset of patients achieve durable benefit. The spatial organization of the tumour microenvironment (TME) and its relationship to immunotherapy response remain incompletely understood. Methods: We i...
Ming-Xiu Cai, Kai-Heng Hu, Hai-Chang Wang et al.
· Cancers · 0 citations